(via TheNewswire)

Calgary, Alberta – TheNewswire - May 14, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce it has successfully manufactured its inaugural accommodating intraocular lenses (the “Ocumetics Lens”) for use in its upcoming first-in-human (FIH) clinical study planned for summer 2025. Each Ocumetics Lens produced has demonstrated, using the IOLA lens analyzer, consistent quality and precision in alignment with study requirements and stringent clinical standards.

Dean Burns, President and CEO of Ocumetics, stated: “Our international design teams have worked diligently to refine and validate our production protocols. I’m confident that the manufacturing processes developed by our team will deliver the consistency in lens quality that is not only essential for clinical trial success but also vital to Ocumetics’ long-term vision of commercial scalability. This is a proud moment for the team as we prepare to deliver a transformative technology into clinical use.”

The Ocumetics Lenses, developed from the finalized prototype design, were manufactured under controlled conditions and subjected to a comprehensive ISO quality assurance process. IOLA test results confirm the reproducibility and stability of the lens characteristics, including the proprietary optical profile and accommodative mechanics, ensuring reliability for human implantation.

Dr. Garth Webb, Founder and Chief Scientific Officer of Ocumetics, shared his enthusiasm: “Achieving consistent quality across manufactured lenses is a critical benchmark. It reinforces our belief in the robustness of our design and the integrity of our manufacturing processes. This step brings us closer to realizing the promise of restoring dynamic, natural vision for patients.”

Manufacturing and validation were performed at the Bioana laboratory in Mexico, supported by verifications at AMIPLANT, Germany. These activities are in preparation for regulatory submission and initiation of the FIH study. Ocumetics remains focused on ensuring the highest levels of safety, performance, and innovation as it moves forward with its clinical development.

Sterility validation on the Ocumetics Lenses is required prior to human implantation. This process has commenced and is expected to take approximately 30 days to complete.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.  

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns                                Roger Jewett

President and CEO                        Chief Financial Officer

(817) 874-7564                                roger.jewett@ocumetics.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Copyright (c) 2025 TheNewswire - All rights reserved.